# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst David Hoang maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price target from ...
Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the ...
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizu...
Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the ...
Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $...
B. Riley Securities analyst Kalpit Patel maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price t...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains...
Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treat...